Ignite Creation Date:
2024-05-05 @ 11:38 AM
Last Modification Date:
2024-10-26 @ 9:10 AM
Study NCT ID:
NCT00094146
Status:
COMPLETED
Last Update Posted:
2009-09-22
First Post:
2004-10-14
Brief Title:
Sandostatin LAR Depot in Patients With Primary Insulin Hypersecretion PIH and at Least Moderate Obesity
Sponsor:
Novartis
Organization:
Novartis
Study Overview
Official Title:
None
Status:
COMPLETED
Status Verified Date:
2004-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This study is in patients with at least moderate obesity Body Mass Index BMI 30 kgm2 or approximately 30 or more pounds overweight and who also produce too much insulin insulin stores sugar as fat Sandostatin LAR Depot suppresses insulin and is being developed to help with weight loss in people who find it hard to lose weight on their own because they produce too much insulin
The main purpose of the study is to find the lowest dose of Sandostatin LAR Depot that safely helps overweight people lose weight The study will also compare weight loss in obese patients who receive one of three different dosages of Sandostatin LAR Depot or placebo
The main purpose of the study is to find the lowest dose of Sandostatin LAR Depot that safely helps overweight people lose weight The study will also compare weight loss in obese patients who receive one of three different dosages of Sandostatin LAR Depot or placebo
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| US20 | None | None | None |